Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 16, 2025Expert Review of Anticancer Therapy

Efficacy and safety of first-line immune checkpoint inhibitors in patients with PD-L1 < 1% metastatic non-small-cell lung cancer – implications for daily clinical practice

View Full Paper
Ask AI
Bookmark
Share

Authors

MBMaciej BrylPoznan University of Medical SciencesKSKatarzyna StencelGreater Poland Cancer CenterMKMagdalena Knetki‐WróblewskaNational Institute of Oncology

Discussion

Loading...

Member takes

Implication

Exploratory analysis highlights immunotherapy benefits for patients with PD-L1 < 1%, suggesting optimal treatment strategies.

Key Points

  • Dual immunotherapy with nivolumab and ipilimumab combined with chemotherapy offers advantages in overall survival.
  • Current evidence indicates that PD-1/PD-L1 inhibitors combined with other therapies may improve progression-free survival.
  • Exploratory analyses show that treatment strategies need further investigation to determine the best options for patients.
  • A lack of defined optimal treatment strategies exists for patients with advanced metastatic non-small cell lung cancer.

Cite This Study

Bryl et al. (2025) studied this question.

synapsesocial.com/papers/68d4205e713b0b5dfea694a2https://doi.org/10.1080/14737140.2025.2557610
View Full Paper
Ask AI
Bookmark
Share